HC Wainwright resumed coverage on Kezar Life Sciences with a new price target
$KZR
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright resumed coverage of Kezar Life Sciences with a rating of Buy and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2023 | $4.00 | Overweight → Equal Weight | Wells Fargo |
| 3/16/2023 | Outperform → Mkt Perform | William Blair | |
| 12/8/2021 | $19.00 | Overweight | Wells Fargo |
| 11/16/2021 | $12.00 → $20.00 | Buy | HC Wainwright & Co. |
| 7/20/2021 | $14.00 | Buy | JonesTrading |
10-Q - Kezar Life Sciences, Inc. (0001645666) (Filer)
8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)
DEFA14A - Kezar Life Sciences, Inc. (0001645666) (Filer)
Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00
William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform
Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00